medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2015-9-34-38medsovet-242Research ArticleКОНТРАЦЕПЦИЯ И ЭНДОКРИННАЯ ГИНЕКОЛОГИЯCONTRACEPTION AND ENDOCRINE GYNECOLOGYНовые возможности коррекции нарушений функции репродуктивной системы при синдроме поликистозных яичниковNew prospects in the management of functional reproductive disorders associated with polycystic ovary syndromeЧернухаГ. Е.ChernukhaG. E.noemail@neicon.ruКапринаЕ. К.KaprinaE. K.noemail@neicon.ruНайдуковаА. А.NaidukovaA. A.noemail@neicon.ruНаучный центр акушерства и гинекологии и перинатологии им. акад. В.И. Кулакова Минздрава России, МоскваРоссияScientific center for obstetrics, gynecology and perinatology named after V.I. Kulakov, Russia’s Ministry of Health, MoscowRussian Federation201530122015093438Copyright © Чернуха Г.Е., Каприна Е.К., Найдукова А.А., 20152015Чернуха Г.Е., Каприна Е.К., Найдукова А.А.Chernukha G.E., Kaprina E.K., Naidukova A.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/242

Синдром поликистозных яичников (СПКЯ) - наиболее распространенная эндокринопатия у женщин репродуктивного возраста, ассоциированная с гиперандрогенией, ановуляторным бесплодием, метаболическими нарушениями. Наряду с гормональными препаратами, при синдроме поликистозных яичников для коррекции нарушений репродуктивной системы применяются лекарственные средства, повышающие чувствительность к инсулину, снижающие секрецию инсулина и андрогенов. Проведенный анализ литературы показал, что мио-инозитол - один из девяти стереоизомеров шестиатомного спирта инозитола - также способствует нормализации ритма менструаций, восстановлению овуляции и созреванию зрелых ооцитов, а также снижению инсулинорезистентности, гиперандрогении. Мио-инозитол считается перспективным веществом в терапии СПКЯ, значительно улучшает результаты программы ЭКО.

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age associated with hyperandrogenism, anovulatory infertility and metabolic disorders. Along with hormonal therapy, reproductive disorders associated with polycystic ovary syndrome are managed with the help of drugs which increase insulin sensitivity, reduce secretion of insulin and androgens. A literature review demonstrated that myo-inositol, one of nine stereoisomers of hexa-hydroxy alcohol inositol, also helps to regulate the menstrual cycle, restore ovulation and maturation of oocytes, as well as reduces insulin resistance and hyperandrogenism. Myo-inositol seems to be promising in the treatment of PCOS and significantly improves IVF results.

синдром поликистозных яичников (СПКЯ)инсулинорезистентностьгиперинсулинемиятерапияметформинpolycystic ovary syndrome (PCOS)insulin resistancehyperinsulinemiatherapymetforminmyo-inositolReferencesFranks S. Polycystic ovary syndrome. N EngL J Med 1995; 333: 853-861.Franks S. Polycystic ovary syndrome. N EngL J Med 1995; 333: 853-861.The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and Long-term heaLth risks reLated to poLycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47. Review.The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and Long-term heaLth risks reLated to poLycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47. Review.FaLsetti L, Gambera A, Andrico S, Sartori F. Acne and hirsutism in poLycystic ovary syndrome: cLinicaL, endocrinemetaboLic and uLtrasono-graphic differences. Gynaecol Endocrinol 2002: 16: 274-284.FaLsetti L, Gambera A, Andrico S, Sartori F. Acne and hirsutism in poLycystic ovary syndrome: cLinicaL, endocrinemetaboLic and uLtrasono-graphic differences. Gynaecol Endocrinol 2002: 16: 274-284.BaiLLargeon JP, luorno MJ, NestLer JE. Insulin sensitizers for poLycystic ovary syndrome. Clin Obstet Gynecol 2003; 46: 325 340.BaiLLargeon JP, luorno MJ, NestLer JE. Insulin sensitizers for poLycystic ovary syndrome. Clin Obstet Gynecol 2003; 46: 325 340.CatraLL FR, HeaLy DL. Long term metaboLic, cardiovascuLar and neopLastic risks with poLycystic ovary syndrome. Best Pract Res Clin Obstet Gynecol 2004; 18: 803-812.CatraLL FR, HeaLy DL. Long term metaboLic, cardiovascuLar and neopLastic risks with poLycystic ovary syndrome. Best Pract Res Clin Obstet Gynecol 2004; 18: 803-812.NestLer JE. RoLe of hyperinsuLinemia in the pathogenesis of the poLycystic ovary syndrome, and its cLinicaL impLications. Semin Reprod Endocrinol 1997; 15: 111-122.NestLer JE. RoLe of hyperinsuLinemia in the pathogenesis of the poLycystic ovary syndrome, and its cLinicaL impLications. Semin Reprod Endocrinol 1997; 15: 111-122.Burghen GA, Givens JR, Kitabchi AE. CorreLation of hyperandrogenism with hyperinsuLinism in poLycystic ovarian disease. J Clin Endocrinol Metab. 1980 Jan; 50(1): 113-6.Burghen GA, Givens JR, Kitabchi AE. CorreLation of hyperandrogenism with hyperinsuLinism in poLycystic ovarian disease. J Clin Endocrinol Metab. 1980 Jan; 50(1): 113-6.Unfer V, CarLomagno G, Dante G, Facchinetti F. Effects of myo-inositoL in women with PCOS: a systematic review of randomized controLLed triaLs. Gynecol Endocrinol 2012; 28: 509-515.Unfer V, CarLomagno G, Dante G, Facchinetti F. Effects of myo-inositoL in women with PCOS: a systematic review of randomized controLLed triaLs. Gynecol Endocrinol 2012; 28: 509-515.Dunaif A. InsuLin resistance in women with poLycystic ovary syndrome. Fertil Steril 2006; 86(SuppL1): S13-14.Dunaif A. InsuLin resistance in women with poLycystic ovary syndrome. Fertil Steril 2006; 86(SuppL1): S13-14.Moran LJ, Hutchison SK, Norman RJ, Teede HJ. 6. Review. LifestyLe changes in women with poLycystic ovary syndrome. Cochrane Database Syst Rev. 2011 JuL 6; (7): CD00750.Moran LJ, Hutchison SK, Norman RJ, Teede HJ. 6. Review. LifestyLe changes in women with poLycystic ovary syndrome. Cochrane Database Syst Rev. 2011 JuL 6; (7): CD00750.BaiLLargeon JP, Iuorno MJ, NestLer JE. InsuLin sensitizers for poLycystic ovary syndrome. Clin Obstet Gynecol 2003; 46: 325-340.BaiLLargeon JP, Iuorno MJ, NestLer JE. InsuLin sensitizers for poLycystic ovary syndrome. Clin Obstet Gynecol 2003; 46: 325-340.Genazzani AD, BattagLia C, MaLavasi B, Strucchi C, TortoLani F, Gamba O. Metformin administration moduLates and restores Luteinizing hormones-pontaneous episodic secretion and ovarian function in nonobese patients with poLycystic ovary syndrome. Fertil Steril 2004; 81: 114-119.Genazzani AD, BattagLia C, MaLavasi B, Strucchi C, TortoLani F, Gamba O. Metformin administration moduLates and restores Luteinizing hormones-pontaneous episodic secretion and ovarian function in nonobese patients with poLycystic ovary syndrome. Fertil Steril 2004; 81: 114-119.Dunn CJ, Peters DH. Metformin: a review of its pharmacoLogicaL properties and therapeutic uses in non-insuLin dependent diabetes. Drugs 1995; 49: 721-749.Dunn CJ, Peters DH. Metformin: a review of its pharmacoLogicaL properties and therapeutic uses in non-insuLin dependent diabetes. Drugs 1995; 49: 721-749.SaLtieL AR. Second messengers of insuLin action. Diabetes care 1990; 13: 244-256.SaLtieL AR. Second messengers of insuLin action. Diabetes care 1990; 13: 244-256.Romero G, Larner J. InsuLin mediators and the mechanism of insuLin action. Adv Pharmacol 1993; 24: 21-50.Romero G, Larner J. InsuLin mediators and the mechanism of insuLin action. Adv Pharmacol 1993; 24: 21-50.AspLin I, GaLasko G, Larner J. Chiro-inositoL deficiency and insuLin resistance: a comparison of the chi-ro-inositoL- and the myo-inositoL-containing insuLin mediators isoLated from urine, hemodiaLysate, and muscLe of controL and type II diabeticsubjects. Proc Natl Acad Sci USA 1993; 90: 5924-5928.AspLin I, GaLasko G, Larner J. Chiro-inositoL deficiency and insuLin resistance: a comparison of the chi-ro-inositoL- and the myo-inositoL-containing insuLin mediators isoLated from urine, hemodiaLysate, and muscLe of controL and type II diabeticsubjects. Proc Natl Acad Sci USA 1993; 90: 5924-5928.BaiLLargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, NestLer JE. Metformin therapy increases insuLin-stimuLated reLease of D-chiro-inositoL-containing inositoLphosphogLycan mediator in women with poLycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 242-249.BaiLLargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, NestLer JE. Metformin therapy increases insuLin-stimuLated reLease of D-chiro-inositoL-containing inositoLphosphogLycan mediator in women with poLycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 242-249.Lord JM, FLight IH, Norman RJ. Metformin in poL-ycystic ovary syndrome: systematic review and meta-anaLysis. Br Med J 2003; 327: 951-957.Lord JM, FLight IH, Norman RJ. Metformin in poL-ycystic ovary syndrome: systematic review and meta-anaLysis. Br Med J 2003; 327: 951-957.Kennington AS, HiLL CR, Craig J, Bogardus C, Raz I, Ortmeyer HK, Hansen BC, Romero G, Larner J. Low urinary chiro-inositoL excretion in non-insuLindependent diabetes meLLitus. N Engl J Med 1990; 323: 373-378.Kennington AS, HiLL CR, Craig J, Bogardus C, Raz I, Ortmeyer HK, Hansen BC, Romero G, Larner J. Low urinary chiro-inositoL excretion in non-insuLindependent diabetes meLLitus. N Engl J Med 1990; 323: 373-378.AspLin I, GaLasko G, Larner J. chiro-inositoL deficiency and insuLin resistance: a comparison of the chiro-inositoL- and the myo-inositoL-con-taining insuLin mediators isoLated from urine, hemodiaLysate, and muscLe of controL and type II diabetic subjects. Proc Natl Acad Sci USA 1993; 90: 5924-5928.AspLin I, GaLasko G, Larner J. chiro-inositoL deficiency and insuLin resistance: a comparison of the chiro-inositoL- and the myo-inositoL-con-taining insuLin mediators isoLated from urine, hemodiaLysate, and muscLe of controL and type II diabetic subjects. Proc Natl Acad Sci USA 1993; 90: 5924-5928.COHEN P. The twentieth century struggLe to decipher insuLin signaLLing. Nat RevMol Cell Biol 2006; 7: 867-873.COHEN P. The twentieth century struggLe to decipher insuLin signaLLing. Nat RevMol Cell Biol 2006; 7: 867-873.BaiLLargeon JP, NestLer JE, OstLund RE, Apridonidzet, Diamanti-Kandarakis E. Greek hyperinsuLinemic women, with or without poLycystic ovary syndrome, dispLay aLtered inositoLs metaboLism. Hum Reprod 2008; 23: 1439-1446.BaiLLargeon JP, NestLer JE, OstLund RE, Apridonidzet, Diamanti-Kandarakis E. Greek hyperinsuLinemic women, with or without poLycystic ovary syndrome, dispLay aLtered inositoLs metaboLism. Hum Reprod 2008; 23: 1439-1446.BaiLLargeon JP, Diamanti-Kandarakis E, OstLund RE, JR., Apridonidze T, Iuorno MJ, NestLer JE. ALtered D-chiro-inositoL urinary cLearance in women with poLycystic ovary syndrome. Diabetes Care 2006; 29: 300-305.BaiLLargeon JP, Diamanti-Kandarakis E, OstLund RE, JR., Apridonidze T, Iuorno MJ, NestLer JE. ALtered D-chiro-inositoL urinary cLearance in women with poLycystic ovary syndrome. Diabetes Care 2006; 29: 300-305.Gerasimenko JV, FLowerdew SE, Voronina SG et aL. BiLe acids induce Ca reLease from both the endopLasmic reticuLum and acidic intraceLLuLar caLcium stores through activation of inositoL trisphosphate receptors and ryanodine receptors J. Biol. Chem. 2006. 281. 52. 40154-40163.Gerasimenko JV, FLowerdew SE, Voronina SG et aL. BiLe acids induce Ca reLease from both the endopLasmic reticuLum and acidic intraceLLuLar caLcium stores through activation of inositoL trisphosphate receptors and ryanodine receptors J. Biol. Chem. 2006. 281. 52. 40154-40163.Larner J.D-chiro-inositoL - its functionaL roLe in insuLin action and its deficit in insuLin resistance Int. J. Exp. Diabetes. Res. 2002. 3. 1. 47-60.Larner J.D-chiro-inositoL - its functionaL roLe in insuLin action and its deficit in insuLin resistance Int. J. Exp. Diabetes. Res. 2002. 3. 1. 47-60.

The authors declare that there are no conflicts of interest present.